Figure 5.
Clonal relapse dynamics of patients based on detectable DTA and non-DTA molecular markers. Relapse DTA (DNMT3A, TET2, ASXL1) and non-DTA mutations were, if possible, repetitively monitored by NGS-MRD. Total number of prerelapse NGS analyses of DTA mutations: n = 69; median, 1; range, 1-5. Total number of prerelapse NGS analyses of non-DTA-mutations: n = 227; median, 1; range, 1-6. , .